NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.03. The biopharmaceutical company had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.44 million. Acceleron Pharma had a negative net margin of 353.57% and a negative return on equity of 30.79%. The business's revenue was up 27.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.63) EPS. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Acceleron Pharma.

12 analysts have issued 1-year target prices for Acceleron Pharma's shares. Their forecasts range from $45.00 to $88.00. On average, they anticipate Acceleron Pharma's share price to reach $60.45 in the next twelve months. This suggests a possible upside of 21.2% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Media stories about XLRN stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acceleron Pharma earned a news impact score of -1.1 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Acceleron Pharma.

Some companies that are related to Acceleron Pharma include Qiagen (QGEN), BIO-TECHNE (TECH), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), Repligen (RGEN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), LogicBio Therapeutics (LOGC), Incyte (Incy), Corcept Therapeutics (CORT), Cisco Systems (CSCO), Exelixis (EXEL), Gilead Sciences (Gild), Intercept Pharmaceuticals (ICPT), FibroGen (FGEN) and NVIDIA (NVDA).

Acceleron Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (2.74%), State Street Corp (2.68%), TimesSquare Capital Management LLC (1.99%), Eagle Asset Management Inc. (1.74%), Granahan Investment Management Inc. MA (0.41%) and Alps Advisors Inc. (0.20%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Christopher Rovaldi, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., State Street Corp, State of New Jersey Common Pension Fund D, Squarepoint Ops LLC, Neville Rodie & Shaw Inc., SG Americas Securities LLC, Alps Advisors Inc. and Mackay Shields LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin and Ravindra Kumar. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Millennium Management LLC, Russell Investments Group Ltd., California Public Employees Retirement System, Man Group plc, Eagle Asset Management Inc., Granahan Investment Management Inc. MA and Great Point Partners LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $49.88.

Acceleron Pharma has a market capitalization of $2.65 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]